0000888491-20-000030.txt : 20200504 0000888491-20-000030.hdr.sgml : 20200504 20200504165808 ACCESSION NUMBER: 0000888491-20-000030 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20200504 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200504 DATE AS OF CHANGE: 20200504 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OMEGA HEALTHCARE INVESTORS INC CENTRAL INDEX KEY: 0000888491 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 383041398 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11316 FILM NUMBER: 20845672 BUSINESS ADDRESS: STREET 1: 303 INTERNATIONAL CIRCLE, STREET 2: SUITE 200 CITY: HUNT VALLEY STATE: MD ZIP: 21030 BUSINESS PHONE: 410-427-1700 MAIL ADDRESS: STREET 1: 303 INTERNATIONAL CIRCLE, STREET 2: SUITE 200 CITY: HUNT VALLEY STATE: MD ZIP: 21030 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OHI Healthcare Properties Limited Partnership CENTRAL INDEX KEY: 0001639315 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 364796206 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-203447-11 FILM NUMBER: 20845671 BUSINESS ADDRESS: STREET 1: C/O OMEGA HEALTHCARE INVESTORS, INC. STREET 2: 200 INTERNATIONAL CIRCLE, STE. 3500 CITY: HUNT VALLEY STATE: MD ZIP: 21030 BUSINESS PHONE: 410-427-1700 MAIL ADDRESS: STREET 1: C/O OMEGA HEALTHCARE INVESTORS, INC. STREET 2: 200 INTERNATIONAL CIRCLE, STE. 3500 CITY: HUNT VALLEY STATE: MD ZIP: 21030 8-K 1 ohi-20200504x8k.htm 8-K
000088849100016393158-Kfalsefalse2020-05-04Suite 200Hunt Valley21030410427-1700falsefalsefalsefalsefalseMD303 International Circle,0000888491srt:PartnershipInterestMember2020-05-042020-05-0400008884912020-05-042020-05-04

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

​ ​​ ​

FORM 8-K

​ ​​ ​

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 4, 2020

OMEGA HEALTHCARE INVESTORS, INC.

OHI HEALTHCARE PROPERTIES LIMITED PARTNERSHIP

(Exact name of registrant as specified in its charter)

Maryland

1-11316

38-3041398

(Omega Healthcare Investors, Inc.)

(Omega Healthcare Investors, Inc.)

(Omega Healthcare Investors, Inc.)

Delaware

33-203447-11

36-4796206

(OHI Healthcare Properties Limited Partnership)

(OHI Healthcare Properties Limited Partnership)

(OHI Healthcare Properties Limited Partnership)

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

303 International Circle,

Suite 200

Hunt Valley, Maryland 21030

(Address of principal executive offices / Zip Code)

(410) 427-1700

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     Written communications pursuant to Rule 425 under the Securities Act.

     Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $.10 par value

OHI

New York Stock Exchange

Item 2.02     Regulation FD Disclosure

On May 4, 2020, Omega Healthcare Investors, Inc. (“Omega”) issued a press release regarding its financial results for the quarter ended March 31, 2020.  Omega’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

The information in this Item 2.02 of this Current Report on Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01     Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description of Exhibit

99.1Press release issued by the Company on May 4, 2020.

104Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

OMEGA HEALTHCARE INVESTORS, INC.

(Co-Registrant)

Dated: May 4, 2020

By:

/s/ Gail D. Makode

Gail D. Makode

Chief Legal Officer, General Counsel

OHI HEALTHCARE PROPERTIES LIMITED PARTNERSHIP

(Co-Registrant)

Dated: May 4, 2020

By:

Omega Healthcare Investors, Inc., its General Partner

/s/ Gail D. Makode

Gail D. Makode

Chief Legal Officer, General Counsel

EX-99.1 2 ohi-20200504ex9919771de.htm EX-99.1 ohi_Ex99_1

Exhibit 99.1

 

Picture 2

303 International Circle       P: 410.427.1700

Suite 200                                F: 410.427.8800

Hunt Valley, MD 21030

 

PRESS RELEASE – FOR IMMEDIATE RELEASE

OMEGA REPORTS FIRST QUARTER 2020 RESULTS

Enhances Strong Balance Sheet during COVID-19 Uncertainties

 

HUNT VALLEY, MARYLAND – May 4, 2020 – Omega Healthcare Investors, Inc. (NYSE:OHI) (the “Company” or “Omega”) today announced its results for the quarter ended March 31, 2020.  The Company reported net income of $92.3 million or $0.39 per common share. The Company also reported NAREIT Funds From Operations (“NAREIT FFO”) for the quarter of $181.0 million or $0.77 per common share, Adjusted Funds From Operations (“AFFO” or “Adjusted FFO”) of $186.2 million or $0.79 per common share, and Funds Available for Distribution (“FAD”) of $174.3 million.

NAREIT FFO, AFFO and FAD are supplemental non-GAAP financial measures that we believe are useful in evaluating the performance of real estate investment trusts.  For more information regarding these non-GAAP measures, see the “Funds From Operations” schedule below and the Company’s website at www.omegahealthcare.com.

 

GAAP NET INCOME

 

For the quarter ended March 31, 2020, the Company reported net income of $92.3 million, or $0.39 per common share, on revenues of $253.0 million.  This compares to net income of $72.2 million, or $0.34 per common share, on revenues of $223.7 million, for the same period in 2019.  The increase in net income was primarily due to (i) $29.3 million in revenue from incremental new investments, (ii) a $4.1 million decrease in impairments on direct financing leases and real estate properties and (iii) a $3.2 million decrease in merger related costs.  The increase in net income was partially offset by an $11.8 million increase in depreciation and amortization expense and  a $4.6 million increase in interest expense, both related to new investments.

 

CEO COMMENTS

 

Taylor Pickett, Omega’s Chief Executive Officer, stated, “While we are pleased to announce strong first quarter results, we recognize that investors are more focused on how our operators are weathering the impact of COVID-19 on their facilities and how this is affecting their capacity to pay our rent.  It is a challenging period on all fronts for our operators.  As well as dealing with an unprecedented pandemic, which has proved particularly dangerous to their frail and vulnerable residents, they have seen declining occupancy and significantly elevated costs combine to materially impact their financial performance.  Thankfully, the various federal and state agencies that oversee skilled nursing have acted quickly and effectively to provide financial support to the industry, allowing operators to focus on their primary job of caring for their residents.”

 

Mr. Pickett continued, “While the full extent of the impact of COVID-19 and its potential short-term impact on our operations has yet to be seen, we believe that the attractive elements of this asset class, with its needs-based nature, constrained supply and escalating demand, will remain intact once this pandemic has been resolved.”

 

Mr. Pickett concluded, “We are proud of the tremendous efforts of our operators and their heroic staff, risking their own health and that of their families to protect and care for their residents.  We believe their bravery has received insufficient recognition, but we are aware of the sacrifices they are making, and we continue to stand ready to provide them the support and help they need at this extraordinary time.”

 

2020 RECENT DEVELOPMENTS AND FIRST QUARTER HIGHLIGHTS

 

In Q2 2020, the Company

 

·

declared a $0.67 per share quarterly common stock dividend.

·

sold five facilities for $39 million in cash generating $17 million in gains.

 

In Q1 2020, the Company

 

·

suspended its Dividend Reinvestment and Stock Purchase Plan.

·

sold six facilities for $18 million in cash proceeds generating $2 million in gains.

·

completed $19 million of new investments.

·

invested $39 million in capital renovation and construction-in-progress projects.

·

authorized $200 million stock repurchase program.

·

paid a $0.67 per share quarterly common stock dividend.

 

FIRST QUARTER 2020 RESULTS

 

Operating Revenues and Expenses – Revenues for the quarter ended March 31, 2020 totaled $253.0 million, which included $10.8 million of non-cash revenue, $3.4 million of real estate tax and ground rents and $0.7 million of one-time revenue.

Expenses for the quarter ended March 31, 2020 totaled $107.1 million, consisting of $82.6 million of depreciation and amortization expense, $10.9 million of general and administrative (“G&A”) expense, $4.6 million of stock-based compensation expense, $4.0 million of real estate tax and ground lease expense, $3.6 million of impairment on real estate properties and a $1.5 million provision for credit losses (resulting from the adoption of a new accounting standard as required by the Financial Accounting Standards Board).

Other Income and Expense – Other income and expense for the quarter ended March 31, 2020 was a net expense of $56.0 million, primarily consisting of $52.7 million of interest expense and $2.5 million of amortized deferred financing costs.

Funds From Operations – For the quarter ended March 31, 2020, NAREIT FFO was $181.0 million, or $0.77 per common share, on 235 million weighted-average common shares outstanding, compared to $144.1 million, or $0.67 per common share, on 214 million weighted-average common shares outstanding, for the same period in 2019.

The $181.0 million of NAREIT FFO for the quarter ended March 31, 2020 includes $4.6 million of non-cash stock-based compensation expense and a $1.5 million provision for credit losses offset by $0.7 million of one-time revenue and a $0.2 million adjustment for merger related costs.

The $144.1 million of NAREIT FFO for the quarter ended March 31, 2019 includes $7.7 million in impairments on direct financing leases, $4.1 million of non-cash stock-based compensation expense, $2.9 million of merger related costs, a $1.2 million write-off of non-cash revenue, a $1.1 million one-time lease termination payment, $1.0 million of restructuring costs and $1.0 million of one-time revenue.

Adjusted FFO was $186.2 million, or $0.79 per common share, for the quarter ended March 31, 2020, compared to $161.3 million, or $0.76 per common share, for the same quarter in 2019.  For further information see the “Funds From Operations” schedule below and the Company’s website.

FINANCING ACTIVITIES

 

Hedging – On March 27, 2020, the Company entered into $400 million (notional amount) of 10-year interest rate swaps at an average rate of 0.8675% that expire in 2024.

Liquidity – In March, the Company, under an abundance of caution, borrowed approximately $300 million under its revolving credit facility to provide additional balance sheet liquidity.  At April 30, 2020, the Company had $618 million of outstanding borrowings under its $1.25 billion credit facility and had approximately $490 million in invested cash.

$200 Million Stock Repurchase Program –  In March, the Board of Directors authorized a program allowing the repurchase of up to $200 million of Omega’s outstanding common stock through March 2021.  The timing and amount of stock repurchases is at the discretion of management; however, management is under no obligation to repurchase any amount of stock.  No shares of stock were repurchased for the period ended April 30, 2020.

Equity Shelf Program and Dividend Reinvestment and Common Stock Purchase Plan – On March 23, 2020, considering current equity market conditions, the Company suspended its Dividend Reinvestment and Common Stock Purchase Plan until further notice.  During the quarter ended March 31, 2020, the Company sold 0.1 million shares of its common stock, generating $5.7 million of gross proceeds under its Equity Shelf Program and its Dividend Reinvestment and Common Stock Purchase Plan:

 

 

 

 

 

 

 

 

    

Equity Shelf

    

Dividend

 

 

(At-the-

 

Reinvestment and

 

 

Market)

 

Common Stock

(in thousands, except price per share)

 

Program

 

Purchase Plan

 

 

Q1 2020

 

 

 

 

 

 

Number of shares

 

 

49

 

 

90

Average price per share

 

$

41.05

 

$

41.80

Gross proceeds

 

$

2,000

 

$

3,747

 

2020 FIRST QUARTER PORTFOLIO AND RECENT ACTIVITY

 

Q1 Portfolio Activity:

 

$58 Million of New Investments in Q1 2020 – In the first quarter of 2020, the Company completed approximately $19 million of new investments and $39 million in capital renovations and new construction projects consisting of the following:

 

$12 Million Acquisition – On March 10, 2020, the Company acquired two care home facilities (similar to assisted living facilities in the United States) located in the United Kingdom (“UK”) from an unrelated third party for approximately $12.1 million. The two facilities with 74 beds were added to an existing operator’s master lease with an initial annual cash yield of 8.0% with 2.5% annual escalators.

 

$7 Million Acquisition – On January 2, 2020, the Company acquired one skilled nursing facility (“SNF”) located in Indiana from an unrelated third party for approximately $7.0 million. The 130-bed facility was added to an existing operator’s master lease with an initial annual cash yield of 9.5% with 2.5% annual escalators.

 

$39 Million of New InvestmentsIn the first quarter of 2020, the Company invested $39 million under its capital renovation and construction-in-progress programs.

 

Asset Sales and Impairments:

 

$18 Million in Assets Sales – In the first quarter of 2020, the Company sold six properties for $18.1 million in cash, recognizing a gain of approximately $1.8 million.

 

Impairments and Assets Held for Sale – During the first quarter of 2020, the Company recorded an impairment charge of $3.6 million to reduce the net book values on three properties to their estimated fair values or expected selling prices.

 

As of March 31, 2020, the Company had eight properties classified as assets held for sale totaling approximately $24.1 million.

 

On April 1, 2020, the Company sold five of those facilities for $38.6 million in cash, recognizing a gain of approximately $16.7 million.  The Company expects to sell the remaining three properties over the next few quarters.

 

DIVIDENDS

 

On April 13, 2020, the Board of Directors declared a common stock dividend of $0.67 per share, to be paid May 15, 2020 to common stockholders of record as of the close of business on April 30, 2020.

 

2020 GUIDANCE WITHDRAWN

 

Bob Stephenson, Omega’s CFO, commented, “We are pleased with our first quarter earnings and having collected 98% of our April rents and mortgage payments.  However, our 2020 earnings guidance, issued on February 5, 2020, did not include or contemplate any adverse impact from COVID-19.  Given the lack of certainty around the future depth and breadth of this pandemic, its impact on the financial performance of our operators and the extent of future necessary government support, we feel it is prudent to withdraw our 2020 earnings guidance.”

 

CONFERENCE CALL

The Company will be conducting a conference call on Tuesday, May 5, 2020 at 10 a.m. Eastern time to review the Company’s 2020 first quarter results and current developments.  Analysts and investors within the United States interested in participating are invited to call (877) 511-2891.  The Canadian toll-free dial-in number is (855) 669-9657.  All other international participants may use the dial-in number (412) 902-4140.  Ask the operator to be connected to the “Omega Healthcare’s First Quarter 2020 Earnings Call.”

To listen to the conference call via webcast, log on to www.omegahealthcare.com and click the “earnings call” icon on the Company’s home page.  Webcast replays of the call will be available on the Company’s website for two weeks following the call.

*   *   *   *   *   *

Omega is a real estate investment trust that invests in the long-term healthcare industry, primarily in skilled nursing and assisted living facilities.  Its portfolio of assets is operated by a diverse group of healthcare companies, predominantly in a triple-net lease structure.  The assets span all regions within the US, as well as in the UK.

 

FOR FURTHER INFORMATION, CONTACT

Matthew Gourmand, SVP, Investor Relations

or

Bob Stephenson, CFO at (410) 427-1700


Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding Omega’s or its tenants', operators', borrowers' or managers' expected future financial condition, results of operations, cash flows, funds from operations, dividends and dividend plans, financing opportunities and plans, capital markets transactions, business strategy, budgets, projected costs, operating metrics, capital expenditures, competitive positions, acquisitions, investment opportunities, dispositions, facility transitions, growth opportunities, expected lease income, continued qualification as a REIT, plans and objectives of management for future operations and statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will” and other similar expressions are forward-looking statements. These forward-looking statements are inherently uncertain, and actual results may differ from Omega's expectations.

Omega’s actual results may differ materially from those reflected in such forward-looking statements as a result of a variety of factors, including, among other things: (i) uncertainties relating to the business operations of the operators of Omega’s properties, including those relating to reimbursement by third-party payors, regulatory matters and occupancy levels; (ii) the impact of healthcare reform and regulation, including cost containment measures and changes in reimbursement policies, procedures and rates; (iii) the ability of operators and borrowers to maintain the financial strength and liquidity necessary to satisfy their respective rent and debt obligations; (iv) the ability of any of Omega’s operators in bankruptcy to reject unexpired lease obligations, modify the terms of Omega’s mortgages and impede the ability of Omega to collect unpaid rent or interest during the pendency of a bankruptcy proceeding and retain security deposits for the debtor’s obligations, and other costs and uncertainties associated with operator bankruptcies; (v) the availability and cost of capital; (vi) changes in Omega’s credit ratings and the ratings of its debt securities; (vii) competition in the financing of healthcare facilities; (viii) the impact of COVID-19 on Omega’s business and the business of Omega’s operators, including without limitation, the extent and duration of the COVID-19 pandemic, increased costs experienced by SNF and ALF operators in connection therewith, and the extent to which government support may be available to operators to offset such costs and the conditions related thereto; (ix) Omega’s ability to maintain its status as a REIT and the impact of changes in tax laws and regulations affecting REITs; (x) Omega’s ability to sell assets held for sale or complete potential asset sales on a timely basis and on terms that allow Omega to realize the carrying value of these assets; (xi) Omega’s ability to re-lease, otherwise transition or sell underperforming assets on a timely basis and on terms that allow Omega to realize the carrying value of these assets; (xii) the effect of economic and market conditions generally, and particularly in the healthcare industry; (xiii) the potential impact of changes in the SNF and ALF market or local real estate conditions on the Company’s ability to dispose of assets held for sale for the anticipated proceeds or on a timely basis, or to redeploy the proceeds therefrom on favorable terms; (xiv) changes in interest rates; and (xv) other factors identified in Omega’s filings with the SEC. Statements regarding future events and developments and Omega’s future performance, as well as management’s expectations, beliefs, plans, estimates or projections relating to the future, are forward looking statements.

We caution you that the foregoing list of important factors may not contain all the material factors that are important to you. Accordingly, readers should not place undue reliance on those statements. All forward-looking statements are based upon information available to us on the date of this release. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

 

 

OMEGA HEALTHCARE INVESTORS, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except per share amounts)

 

 

 

 

 

 

 

 

 

 

March 31, 

 

December 31, 

 

    

2020

    

2019

 

 

(Unaudited)

 

 

 

ASSETS

 

 

 

 

 

 

Real estate properties

 

 

 

 

 

 

Real estate investments

 

$

8,949,912

 

$

8,985,994

Less accumulated depreciation

 

 

(1,846,992)

 

 

(1,787,425)

Real estate investments – net

 

 

7,102,920

 

 

7,198,569

Investments in direct financing leases – net

 

 

10,850

 

 

11,488

Mortgage notes receivable – net

 

 

754,030

 

 

773,563

 

 

 

7,867,800

 

 

7,983,620

Other investments – net

 

 

424,723

 

 

419,228

Investments in unconsolidated joint ventures

 

 

194,407

 

 

199,884

Assets held for sale – net

 

 

24,125

 

 

4,922

Total investments

 

 

8,511,055

 

 

8,607,654

 

 

 

 

 

 

 

Cash and cash equivalents

 

 

347,965

 

 

24,117

Restricted cash

 

 

4,057

 

 

9,263

Contractual receivables – net

 

 

27,429

 

 

27,122

Other receivables and lease inducements

 

 

398,621

 

 

381,091

Goodwill

 

 

643,536

 

 

644,415

Other assets

 

 

104,568

 

 

102,462

Total assets

 

$

10,037,231

 

$

9,796,124

 

 

 

 

 

 

 

LIABILITIES AND EQUITY

 

 

 

 

 

  

Revolving line of credit

 

$

516,760

 

$

125,000

Term loans – net

 

 

796,523

 

 

804,738

Secured borrowings

 

 

387,835

 

 

389,680

Senior notes and other unsecured borrowings – net

 

 

3,818,531

 

 

3,816,722

Accrued expenses and other liabilities

 

 

288,745

 

 

312,040

Deferred income taxes

 

 

10,192

 

 

11,350

Total liabilities

 

 

5,818,586

 

 

5,459,530

 

 

 

 

 

 

 

Equity:

 

 

 

 

 

  

Common stock $.10 par value authorized – 350,000 shares, issued and outstanding – 226,866 shares as of March 31, 2020 and 226,631 as of December 31, 2019

 

 

22,686

 

 

22,663

Common stock – additional paid-in capital

 

 

5,997,561

 

 

5,992,733

Cumulative net earnings

 

 

2,525,323

 

 

2,463,436

Cumulative dividends paid

 

 

(4,458,207)

 

 

(4,303,546)

Accumulated other comprehensive loss

 

 

(65,788)

 

 

(39,858)

Total stockholders’ equity

 

 

4,021,575

 

 

4,135,428

Noncontrolling interest

 

 

197,070

 

 

201,166

Total equity

 

 

4,218,645

 

 

4,336,594

Total liabilities and equity

 

$

10,037,231

 

$

9,796,124

 

 

 

 

OMEGA HEALTHCARE INVESTORS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

Unaudited

(in thousands, except per share amounts)

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

March 31, 

 

    

2020

    

2019

Operating revenues

 

 

  

 

 

  

Rental income

 

$

218,125

 

$

188,204

Real estate tax and ground lease income

 

 

3,375

 

 

3,973

Income from direct financing leases

 

 

258

 

 

260

Mortgage interest income

 

 

19,685

 

 

18,134

Other investment income

 

 

10,652

 

 

11,914

Miscellaneous income

 

 

929

 

 

1,203

Total operating revenues

 

 

253,024

 

 

223,688

 

 

 

 

 

 

 

Operating expenses

 

 

  

 

 

  

Depreciation and amortization

 

 

82,643

 

 

70,852

General and administrative

 

 

10,927

 

 

11,826

Real estate tax and ground lease expense

 

 

4,027

 

 

4,119

Stock-based compensation

 

 

4,635

 

 

4,070

Acquisition and merger related costs

 

 

(225)

 

 

2,949

Impairment on real estate properties

 

 

3,639

 

 

 —

Impairment on direct financing leases

 

 

 —

 

 

7,700

Provision for credit losses

 

 

1,486

 

 

 —

Total operating expenses

 

 

107,132

 

 

101,516

 

 

 

 

 

 

 

Other operating income

 

 

  

 

 

  

Gain on assets sold – net

 

 

1,838

 

 

 3

Operating income

 

 

147,730

 

 

122,175

 

 

 

 

 

 

 

Other income (expense)

 

 

  

 

 

  

Interest income and other – net

 

 

(734)

 

 

337

Interest expense

 

 

(52,741)

 

 

(48,100)

Interest – amortization of deferred financing costs

 

 

(2,461)

 

 

(2,238)

Realized (loss) gain on foreign exchange

 

 

(70)

 

 

26

Total other expense

 

 

(56,006)

 

 

(49,975)

 

 

 

 

 

 

 

Income before income tax expense and income from unconsolidated joint ventures

 

 

91,724

 

 

72,200

Income tax expense

 

 

(1,005)

 

 

(675)

Income from unconsolidated joint ventures

 

 

1,560

 

 

657

Net income

 

 

92,279

 

 

72,182

Net income attributable to noncontrolling interest

 

 

(2,364)

 

 

(2,480)

Net income available to common stockholders

 

$

89,915

 

$

69,702

 

 

 

 

 

 

 

Earnings per common share available to common stockholders:

 

 

  

 

 

  

Basic:

 

 

  

 

 

  

Net income available to common stockholders

 

$

0.40

 

$

0.34

Diluted:

 

 

  

 

 

  

Net income

 

$

0.39

 

$

0.34

Dividends declared per common share

 

$

0.67

 

$

0.66

Weighted-average shares outstanding, basic

 

 

227,261

 

 

204,558

Weighted-average shares outstanding, diluted

 

 

234,506

 

 

213,523

 

 

OMEGA HEALTHCARE INVESTORS, INC.

FUNDS FROM OPERATIONS

Unaudited

(in thousands, except per share amounts)

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

March 31, 

 

 

2020

    

2019

 

 

 

 

 

 

 

Net income

 

$

92,279

 

$

72,182

Deduct gain from real estate dispositions

 

 

(1,838)

 

 

(3)

Deduct gain from real estate dispositions of unconsolidated joint ventures

 

 

(117)

 

 

 —

Sub-total

 

 

90,324

 

 

72,179

Elimination of non-cash items included in net income:

 

 

  

 

 

  

Depreciation and amortization

 

 

82,643

 

 

70,852

Depreciation - unconsolidated joint ventures

 

 

3,632

 

 

1,372

Add back non-cash provision for impairments on real estate properties

 

 

3,639

 

 

 —

Add back (deduct) unrealized loss (gain) on warrants

 

 

775

 

 

(284)

NAREIT funds from operations (“NAREIT FFO”)

 

$

181,013

 

$

144,119

 

 

 

 

 

 

 

Weighted-average common shares outstanding, basic

 

 

227,261

 

 

204,558

Restricted stock and PRSUs

 

 

1,261

 

 

1,688

Omega OP Units

 

 

5,984

 

 

7,277

Weighted-average common shares outstanding, diluted

 

 

234,506

 

 

213,523

 

 

 

 

 

 

 

NAREIT funds from operations available per share

 

$

0.77

 

$

0.67

 

 

 

 

 

 

 

Adjustments to calculate adjusted funds from operations:

 

 

  

 

 

  

NAREIT FFO

 

$

181,013

 

$

144,119

Deduct one-time revenue

 

 

(666)

 

 

(972)

(Deduct) add back acquisition and merger related costs

 

 

(225)

 

 

2,949

Add back one-time termination payment

 

 

 —

 

 

1,118

Add back impairment for direct financing leases

 

 

 —

 

 

7,700

Add back provision for credit losses

 

 

1,486

 

 

 —

Add back uncollectible accounts (1)

 

 

 —

 

 

1,229

Add back restructuring costs

 

 

 —

 

 

1,040

Add back non-cash stock-based compensation expense

 

 

4,635

 

 

4,070

Adjusted funds from operations (“AFFO”)

 

$

186,243

 

$

161,253

 

 

 

 

 

 

 

Adjustments to calculate funds available for distribution:

 

 

  

 

 

  

Non-cash interest expense

 

$

2,438

 

$

2,213

Capitalized interest

 

 

(3,646)

 

 

(3,453)

Non-cash revenues

 

 

(10,763)

 

 

(14,773)

Funds available for distribution (“FAD”)

 

$

174,272

 

$

145,240

(1) The provision or charges for uncollectible rental revenue accounts (straight-line and contractual) are recorded through rental income.

 

NAREIT Funds From Operations (“NAREIT FFO”), Adjusted FFO and Funds Available for Distribution (“FAD”) are non-GAAP financial measures.  For purposes of the Securities and Exchange Commission’s Regulation G, a non-GAAP financial measure is a numerical measure of a company’s historical or future financial performance, financial position or cash flows that exclude amounts, or is subject to adjustments that have the effect of excluding amounts, that are included in the most directly comparable financial measure calculated and presented in accordance with GAAP in the income statement, balance sheet or statement of cash flows (or equivalent statements) of the company, or include amounts, or is subject to adjustments that have the effect of including amounts, that are excluded from the most directly comparable financial measure so calculated and presented.  As used in this press release, GAAP refers to generally accepted accounting principles in the United States of America. 

Pursuant to the requirements of Regulation G, the Company has provided reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures.

The Company calculates and reports NAREIT FFO in accordance with the definition and interpretive guidelines issued by the National Association of Real Estate Investment Trusts (“NAREIT”), and consequently, NAREIT FFO is defined as net income (computed in accordance with GAAP), adjusted for the effects of asset dispositions and certain non-cash items, primarily depreciation and amortization and impairments on real estate assets, and after adjustments for unconsolidated partnerships and joint ventures and changes in the fair value of warrants.  Adjustments for unconsolidated partnerships and joint ventures will be calculated to reflect funds from operations on the same basis.  The Company believes that NAREIT FFO, Adjusted FFO and FAD are important supplemental measures of its operating performance.  Because the historical cost accounting convention used for real estate assets requires depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time, while real estate values instead have historically risen or fallen with market conditions.  The term funds from operations was designed by the real estate industry to address this issue.  Funds from operations described herein is not necessarily comparable to funds from operations of other real estate investment trusts, or REITs, that do not use the same definition or implementation guidelines or interpret the standards differently from the Company.

Adjusted FFO is calculated as NAREIT FFO excluding the impact of non-cash stock-based compensation and certain revenue and expense items (e.g., acquisition and merger related costs, provisions for uncollectible accounts, provisions for current expected credit losses, etc.). FAD is calculated as Adjusted FFO less non-cash interest expense and non-cash revenue, such as straight-line rent. The Company believes these measures provide an enhanced measure of the operating performance of the Company’s core portfolio as a REIT. The Company’s computation of Adjusted FFO and FAD may not be comparable to the NAREIT definition of funds from operations or to similar measures reported by other REITs, but the Company believes that they are appropriate measures for this Company.

The Company uses these non-GAAP measures among the criteria to measure the operating performance of its business.  The Company also uses FAD among the performance metrics for performance-based compensation of officers. The Company further believes that by excluding the effect of depreciation, amortization, impairments on real estate assets and gains or losses from sales of real estate, all of which are based on historical costs and which may be of limited relevance in evaluating current performance, funds from operations can facilitate comparisons of operating performance between periods and between other REITs.  The Company offers these measures to assist the users of its financial statements in analyzing its operating performance and not as measures of liquidity or cash flow. These non-GAAP measures are not measures of financial performance under GAAP and should not be considered as measures of liquidity, alternatives to net income or indicators of any other performance measure determined in accordance with GAAP.  Investors and potential investors in the Company’s securities should not rely on these non-GAAP measures as substitutes for any GAAP measure, including net income.

 

The following tables present selected portfolio information, including operator and geographic concentrations, and lease and loan maturities:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

As of March 31, 2020

 

As of March 31, 2020

 

    

 

    

Total

    

    

 

# of

    

# of

Balance Sheet Data

 

Total # of

 

Investment

 

% of

 

Operating

 

Operating

 

 

Properties

 

($000’s)

 

Investment

 

Properties (2)

 

Beds (2)

Real estate investments (1)

 

924

 

$

8,960,762

 

92

%  

 

917

 

92,056

Mortgage notes receivable

 

53

 

 

754,030

 

 8

%  

 

49

 

5,465

 

 

977

 

$

9,714,792

 

100

%  

 

966

 

97,521

Assets held for sale

 

 8

 

 

24,125

 

  

 

 

  

 

  

Total investments

 

985

 

$

9,738,917

 

  

 

 

  

 

  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

    

Total

    

 

# of

# of

Investment

Investment Data

 

Total # of

Investment

% of

 

Operating

Operating

per Bed

 

 

Properties

($000’s)

Investment

 

Properties (2)

Beds (2)

($000’s)

SNFs/Transitional care

 

847

 

$

8,133,267

 

84

%  

 

838

 

89,488

 

$

91

Senior housing (3)

 

130

 

 

1,581,525

 

16

%  

 

128

 

8,033

 

$

197

 

 

977

 

$

9,714,792

 

100

%  

 

966

 

97,521

 

$

100

Assets held for sale

 

 8

 

 

24,125

 

 

 

 

 

 

 

 

 

 

Total investments

 

985

 

$

9,738,917

 

 

 

 

 

 

 

 

 

 


(1) Includes two assets under direct financing leases totaling $10.9 million.

(2) Excludes facilities which are non-operating, closed and/or not currently providing patient services.

(3) Includes ALFs, memory care and independent living facilities.

 

 

 

Revenue Composition ($000’s)

 

 

 

 

 

 

 

 

 

Revenue by Investment Type

 

Three Months Ended

 

 

March 31, 2020

Rental property (1)

    

$

218,383

    

86

%

Real estate tax and ground lease income

 

 

3,375

 

 1

%

Mortgage notes

 

 

19,685

 

 8

%

Other investment income and miscellaneous income - net

 

 

11,581

 

 5

%

 

 

$

253,024

 

100

%

 

 

 

 

 

 

 

 

Revenue by Facility Type

 

Three Months Ended

 

    

March 31, 2020

SNFs/Transitional care

 

$

210,073

    

83

%

Senior housing

 

 

27,995

 

11

%

Real estate tax and ground lease income

 

 

3,375

 

 1

%

Other

 

 

11,581

 

 5

%

 

 

$

253,024

 

100

%


(1) Includes two assets under direct financing leases totaling $0.3 million.

 

 

 

 

 

 

 

 

 

 

 

    

    

2020 Q1

% of Total

 

 

 

Annualized

Annualized

 

 

# of

Contractual

Contractual

Rent/Interest Concentration by Operator ($000’s)

 

Properties (1)

Rent/Interest (1)(2)

Rent/Interest 

Ciena

 

69

 

$

95,550

 

10.2

%

Consulate

 

82

 

 

86,204

 

9.2

%

Genesis

 

56

 

 

63,439

 

6.8

%

CommuniCare

 

43

 

 

61,502

 

6.6

%

Maplewood (3)

 

15

 

 

56,503

 

6.0

%

Signature

 

58

 

 

52,889

 

5.7

%

Saber

 

47

 

 

47,071

 

5.0

%

HHC

 

44

 

 

36,658

 

3.9

%

Guardian

 

35

 

 

35,620

 

3.8

%

Airamid

 

33

 

 

28,638

 

3.1

%

Remaining Operators (4)

 

483

 

 

370,128

 

39.7

%

 

 

965

 

$

934,202

 

100.0

%


(1) Excludes properties which are non-operating, closed and/or not currently providing patient services.

(2) Includes mezzanine and term loan interest.

(3) Includes Inspīr Carnegie Hill (f/k/a 2nd Avenue) revenue which is contractually effective 1/1/2020.

(4) Excludes one multi-tenant medical office building.

 

 

 

 

 

 

 

 

 

 

 

    

Total # of

Total

% of Total

Geographic Concentration by Investment ($000’s)

 

Properties (1)

Investment (1)(2)(3)

Investment

Florida

 

129

 

$

1,400,068

 

14.4

%

Texas

 

126

 

 

933,728

 

9.6

%

Michigan

 

50

 

 

677,229

 

6.9

%

Indiana

 

70

 

 

642,169

 

6.6

%

California

 

59

 

 

610,530

 

6.3

%

Ohio

 

54

 

 

590,221

 

6.1

%

Pennsylvania

 

55

 

 

589,701

 

6.0

%

North Carolina

 

41

 

 

349,673

 

3.6

%

Virginia

 

22

 

 

331,787

 

3.4

%

New York (3)

 

 —

 

 

317,205

 

3.3

%

Remaining 30 states

 

314

 

 

2,897,109

 

29.7

%

 

 

920

 

 

9,339,420

 

95.9

%

United Kingdom

 

57

 

 

398,545

 

4.1

%

 

 

977

 

$

9,737,965

 

100.0

%


(1)  Excludes eight properties with total investment of $24.1 million classified as assets held for sale.

(2) Excludes $23 million reserve for credit losses.

(3) Includes Inspīr Carnegie Hill development project.

 

The following tables present operator revenue mix, census and coverage data based on information provided by our operators for the indicated periods ended:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Lease Expirations & Loan Maturities ($000's) (1)

 

As of March 31, 2020

Year

 

Lease (Rent)

Interest Income

Lease (Rent) and Interest Income

% of Total Annualized Contractual Rent/Interest

2020

 

$

1,622

 

$

126

 

$

1,748

 

0.2

%

2021

 

 

4,268

 

 

5,777

 

 

10,045

 

1.1

%

2022

 

 

36,903

 

 

96

 

 

36,999

 

4.0

%

2023

 

 

6,558

 

 

889

 

 

7,447

 

0.8

%

2024

 

 

36,070

 

 

2,911

 

 

38,981

 

4.2

%


(1) Based on annualized 1st quarter 2020 contractual rent and interest.

 

The following tables present operator revenue mix, census and coverage data based on information provided by our operators for the indicated periods ended.  We have not independently verified this information, and we are providing this data for informational purposes only.

 

 

 

 

 

 

 

 

 

 

    

 

  

Medicare /

 

Operator Revenue Mix (1)

 

Medicaid

Insurance

Private / Other

Three-months ended December 31, 2019

 

52.7

%  

34.6

%  

12.7

%

Three-months ended September 30, 2019

 

53.4

%  

33.4

%  

13.2

%

Three-months ended June 30, 2019

 

54.2

%  

33.3

%  

12.5

%

Three-months ended March 31, 2019

 

53.7

%  

34.0

%  

12.3

%

Three-months ended December 31, 2018

 

54.8

%  

33.3

%  

11.9

%


(1) Excludes all facilities considered non-core.

 

 

 

 

 

 

 

Operator Census and Coverage (1)

 

 

 

Coverage Data

 

    

    

Before

After

 

 

Occupancy (2)

Management

Management

 

 

 

Fees

Fees

 

 

 

 

 

 

Twelve-months ended December 31, 2019

 

83.6

%  

1.64x

1.29x

Twelve-months ended September 30, 2019

 

83.4

%  

1.66x

1.30x

Twelve-months ended June 30, 2019

 

83.3

%  

1.66x

1.30x

Twelve-months ended March 31, 2019

 

82.7

%  

1.67x

1.31x

Twelve-months ended December 31, 2018

 

82.8

%  

1.67x

1.32x


(1)Excludes all properties considered non-core.

(2)Based on available (operating) beds.

 

The following table presents a debt maturity schedule as of March 31, 2020:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Debt Maturities ($000’s)

 

Unsecured Debt

 

 

 

 

 

 

Year

 

Line of Credit and Term Loans (1)

Senior Notes/Other (2)

Sub Notes (3)

 

Secured Debt

Total Debt Maturities

2020

 

$

 —

 

$

 —

 

$

 —

 

$

 —

 

$

 —

2021

 

 

516,760

 

 

 —

 

 

13,541

 

 

2,275

 

 

532,576

2022

 

 

799,000

 

 

 —

 

 

 —

 

 

 —

 

 

799,000

2023

 

 

 —

 

 

700,000

 

 

 —

 

 

 —

 

 

700,000

2024

 

 

 —

 

 

400,000

 

 

 —

 

 

 —

 

 

400,000

2025

 

 

 —

 

 

400,000

 

 

 —

 

 

 —

 

 

400,000

Thereafter

 

 

 —

 

 

2,350,000

 

 

 —

 

 

385,560

 

 

2,735,560

 

 

$

1,315,760

 

$

3,850,000

 

$

13,541

 

$

387,835

 

$

5,567,136


(1) The Line of Credit and Term Loans exclude $1.9 million of net deferred financing costs and can be extended into 2022.  The $799 million is comprised of a: $350 million term loan, £100 million term loan (equivalent to $124 million), $75 million term loan to Omega’s operating partnership, $250 million term loan and excludes $2.5 million net deferred financing costs. 

(2) Excludes net discounts and deferred financing costs.

(3) Excludes $0.1 million of fair market valuation adjustments.

 

The following table presents investment activity:

 

 

 

 

 

 

 

 

Investment Activity ($000's)

 

Three Months Ended

 

 

March 31, 2020

Funding by Investment Type

 

$ Amount

    

%

Real property

 

$

19,056

 

32.6

%

Construction-in-progress

 

 

24,063

 

41.1

%

Capital expenditures

 

 

15,418

 

26.3

%

Investment in direct financing leases

 

 

 —

 

 —

%

Mortgages

 

 

 —

 

 —

%

Other

 

 

 —

 

 —

%

Total

 

$

58,537

 

100.0

%

 

GRAPHIC 3 ohi20200504ex9919771de001.jpg GRAPHIC begin 644 ohi20200504ex9919771de001.jpg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ohi-20200504.xsd EX-101.SCH 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 5 ohi-20200504_def.xml EX-101.DEF EX-101.LAB 6 ohi-20200504_lab.xml EX-101.LAB EX-101.PRE 7 ohi-20200504_pre.xml EX-101.PRE JSON 8 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ohi-20200504x8k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 2, "dts": { "definitionLink": { "local": [ "ohi-20200504_def.xml" ] }, "inline": { "local": [ "ohi-20200504x8k.htm" ] }, "labelLink": { "local": [ "ohi-20200504_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "ohi-20200504_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "ohi-20200504.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 29, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 18, "total": 18 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 1, "nsprefix": "ohi", "nsuri": "http://www.omegahealthcare.com/20200504", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "ohi-20200504x8k.htm", "contextRef": "Duration_5_4_2020_To_5_4_2020_jGqy_s_lHUCECRiTn1L2eg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "role": "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "ohi-20200504x8k.htm", "contextRef": "Duration_5_4_2020_To_5_4_2020_jGqy_s_lHUCECRiTn1L2eg", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 1, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "ohi_DocumentAndEntityInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Document and Entity Information [Abstract]", "label": "Document and Entity Information [Abstract]" } } }, "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.omegahealthcare.com/20200504", "xbrltype": "stringItemType" }, "ohi_DocumentAndEntityInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document And Entity Information [Line Items]" } } }, "localname": "DocumentAndEntityInformationLineItems", "nsuri": "http://www.omegahealthcare.com/20200504", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "ohi_DocumentAndEntityInformationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular information of document and entity.", "label": "Document And Entity Information [Table]" } } }, "localname": "DocumentAndEntityInformationTable", "nsuri": "http://www.omegahealthcare.com/20200504", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "srt_PartnershipInterestMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Partnership Interest [Member]", "terseLabel": "Omega OP" } } }, "localname": "PartnershipInterestMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 10 0000888491-20-000030-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000888491-20-000030-xbrl.zip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end XML 11 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Document and Entity Information
May 04, 2020
Document And Entity Information [Line Items]  
Document Type 8-K
Document Period End Date May 04, 2020
Entity Registrant Name OMEGA HEALTHCARE INVESTORS, INC.
Entity Central Index Key 0000888491
Entity Incorporation, State or Country Code MD
Entity File Number 1-11316
Entity Tax Identification Number 38-3041398
Amendment Flag false
Entity Emerging Growth Company false
Entity Address, Address Line One 303 International Circle,
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Hunt Valley
Entity Address, State or Province MD
Entity Address, Postal Zip Code 21030
City Area Code 410
Local Phone Number 427-1700
Title of 12(b) Security Common Stock
Trading Symbol OHI
Security Exchange Name NYSE
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Omega OP  
Document And Entity Information [Line Items]  
Document Type 8-K
Document Period End Date May 04, 2020
Entity Registrant Name OHI HEALTHCARE PROPERTIES LIMITED PARTNERSHIP
Entity Central Index Key 0001639315
Entity Incorporation, State or Country Code DE
Entity File Number 33-203447-11
Entity Tax Identification Number 36-4796206
Amendment Flag false
Entity Emerging Growth Company false
Entity Address, Address Line One 303 International Circle,
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Hunt Valley
Entity Address, State or Province MD
Entity Address, Postal Zip Code 21030
City Area Code 410
Local Phone Number 427-1700
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false

XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 2 95 1 false 1 0 false 0 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.omegahealthcare.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports ohi-20200504x8k.htm ohi-20200504.xsd ohi-20200504_def.xml ohi-20200504_lab.xml ohi-20200504_pre.xml ohi-20200504ex9919771de.htm http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2019-01-31 true false XML 14 ohi-20200504x8k_htm.xml IDEA: XBRL DOCUMENT 0000888491 srt:PartnershipInterestMember 2020-05-04 2020-05-04 0000888491 2020-05-04 2020-05-04 0000888491 0001639315 8-K false false 2020-05-04 Suite 200 Hunt Valley 21030 410 427-1700 false false false false false MD 303 International Circle, 8-K 2020-05-04 OMEGA HEALTHCARE INVESTORS, INC. OHI HEALTHCARE PROPERTIES LIMITED PARTNERSHIP MD 1-11316 38-3041398 DE 33-203447-11 36-4796206 303 International Circle, Suite 200 Hunt Valley MD 21030 410 427-1700 false false false false false Common Stock OHI NYSE XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } EXCEL 16 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 17 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}